Drugs Made In America Acquisition (DMAAR) Accumulated Expenses (2024 - 2025)

Drugs Made In America Acquisition (DMAAR) posted Accumulated Expenses of $302623.0 for Q3 2025, up 105.23% on a QoQ basis from $147453.0 in Q2 2025.

Drugs Made In America Acquisition (DMAAR) Accumulated Expenses (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition's Accumulated Expenses history runs 2 years deep, the most recent figure standing at $302623.0 for Q3 2025.

Quarterly Accumulated Expenses changed N/A year-over-year to $302623.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $302623.0 (changed N/A YoY) and the FY2024 annual result came in at $77280.0, changed N/A from the prior year.
Accumulated Expenses was $302623.0 for Q3 2025 at Drugs Made In America Acquisition, up from $147453.0 in the prior quarter.
Across five years, Accumulated Expenses topped out at $302623.0 in Q3 2025 and bottomed at $77280.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	SIM Acquisition Corp. I	314.52 Mn	314.52 Mn	-
2	Thayer Ventures Acquisition	208.29 Mn	208.29 Mn	-
3	Newbury Street II Acquisition	185.26 Mn	185.26 Mn	-
4	Dynamix	178.78 Mn	178.78 Mn	-
5	Hallmark Venture	103.01 Mn	102.76 Mn	-
6	Voyager Acquisition	99.58 Mn	99.45 Mn	-
7	Gores Holdings X	95.80 Mn	95.37 Mn	-
8	Archimedes Tech SPAC Partners	89.88 Mn	89.88 Mn	-
9	Cohen Circle Acquisition	80.05 Mn	80.05 Mn	-
10	Drugs Made In America Acquisition	1.46 Mn	1.46 Mn	-

Download Data